Jane R Montealegre1,2, Indu Varier3, Christina G Bracamontes4, Laura M Dillon5, Martial Guillaud6, Andrew G Sikora2,7, Michele Follen8, Karen Adler-Storthz5, Michael E Scheurer1,2. 1. a Department of Pediatrics, Baylor College of Medicine , Houston , TX , USA. 2. b Dan L. Duncan Cancer Center, Baylor College of Medicine , Houston , TX , USA. 3. c Department of Pediatrics, Tulane University School of Medicine , New Orleans , LA , USA. 4. d Department of Obstetrics and Gynecology, Texas Tech Health Sciences Center , El Paso , TX , USA. 5. e Department of Diagnostic and Biomedical Sciences, University of Texas School of Dentistry , Houston , TX , USA. 6. f Department of Integrative Oncology, British Columbia Cancer Research Centre , Vancouver , BC , Canada. 7. g Department of Otolaryngology, Baylor College of Medicine , Houston , TX , USA. 8. h Department of Obstetrics and Gynecology, Brookdale University Hospital and Medical Center , Brooklyn , NY , USA.
Abstract
Objective: There are currently three licensed human papillomavirus (HPV) vaccines that protect against cervical cancer. Here we compare the prevalence of bi-, quadri-, and nonavalent vaccine-related HPV genotypes in a multi-ethnic sample of non-Hispanic white, non-Hispanic black, Hispanic, and Asian women. Design: Patients in this analysis (n = 419) represent a subset of women with a previous abnormal Pap test participating in a clinical trial. HPV genotyping was conducted using the Roche Linear Array. Prevalent HPV genotypes were grouped according to their inclusion in each of the vaccines: bivalent (16, 18), quadrivalent (16, 18, 6, 11), and nonavalent (16, 18, 31, 33, 45, 52, 58, 6, 11). Results: The prevalence of HPV genotypes covered by the bi-/quadrivalent vaccines was lowest among non-Hispanic black (15%) and Hispanic women (20%), compared to non-Hispanic white (38%) and Asian women (38%). Across all racial/ethnic groups, a large proportion of infections (38%-49%) were with genotypes included in the nonavalent vaccine. However, the prevalence of HPV genotypes not covered by any vaccine was significantly higher among non-Hispanic black (36%) and Hispanic women (42%), compared to non-Hispanic white (24%) and Asian women (16%) (p < 0.001). Racial/ethnic differences in HPV genotype prevalence were observed when controlling for demographic and sexual behavior characteristics, as well as when restricting the analysis to women with CIN 2+. Conclusion: Our data suggest racial/ethnic differences in the prevalence of vaccine-related HPV genotypes. In particular, non-Hispanic black and Hispanic women had the lowest prevalence of HPV genotypes covered by the bi-/quadrivalent vaccines. While a large proportion of their infections were covered by the nonavalent vaccine, non-Hispanic black and Hispanic women also had the highest prevalence of HPV genotypes not covered by any vaccine.
Objective: There are currently three licensed human papillomavirus (HPV) vaccines that protect against cervical cancer. Here we compare the prevalence of bi-, quadri-, and nonavalent vaccine-related HPV genotypes in a multi-ethnic sample of non-Hispanic white, non-Hispanic black, Hispanic, and Asian women. Design: Patients in this analysis (n = 419) represent a subset of women with a previous abnormal Pap test participating in a clinical trial. HPV genotyping was conducted using the Roche Linear Array. Prevalent HPV genotypes were grouped according to their inclusion in each of the vaccines: bivalent (16, 18), quadrivalent (16, 18, 6, 11), and nonavalent (16, 18, 31, 33, 45, 52, 58, 6, 11). Results: The prevalence of HPV genotypes covered by the bi-/quadrivalent vaccines was lowest among non-Hispanic black (15%) and Hispanic women (20%), compared to non-Hispanic white (38%) and Asian women (38%). Across all racial/ethnic groups, a large proportion of infections (38%-49%) were with genotypes included in the nonavalent vaccine. However, the prevalence of HPV genotypes not covered by any vaccine was significantly higher among non-Hispanic black (36%) and Hispanic women (42%), compared to non-Hispanic white (24%) and Asian women (16%) (p < 0.001). Racial/ethnic differences in HPV genotype prevalence were observed when controlling for demographic and sexual behavior characteristics, as well as when restricting the analysis to women with CIN 2+. Conclusion: Our data suggest racial/ethnic differences in the prevalence of vaccine-related HPV genotypes. In particular, non-Hispanic black and Hispanic women had the lowest prevalence of HPV genotypes covered by the bi-/quadrivalent vaccines. While a large proportion of their infections were covered by the nonavalent vaccine, non-Hispanic black and Hispanic women also had the highest prevalence of HPV genotypes not covered by any vaccine.
Entities:
Keywords:
Human papillomavirus; cervical neoplasia; race/ethnicity; vaccine
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245
Authors: Marylou Cárdenas-Turanzas; Graciela M Nogueras-Gonzalez; Michael E Scheurer; Karen Adler-Storthz; J L Benedet; J Robert Beck; Michele Follen; Scott B Cantor Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10 Impact factor: 4.254
Authors: Suzanne M Garland; Marc Steben; Heather L Sings; Margaret James; Shuang Lu; Radha Railkar; Eliav Barr; Richard M Haupt; Elmar A Joura Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: J R Montealegre; E C Peckham-Gregory; D Marquez-Do; L Dillon; M Guillaud; K Adler-Storthz; M Follen; M E Scheurer Journal: Gynecol Oncol Date: 2017-12-21 Impact factor: 5.482
Authors: Marla J Keller; Robert D Burk; L Stewart Massad; Isam-Eldin Eltoum; Nancy A Hessol; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Laura L Reimers; Mark Kuniholm; Gypsyamber DʼSouza; Christine Colie; Bradley Aouizerat; Joel M Palefsky; Howard D Strickler Journal: AIDS Date: 2018-11-28 Impact factor: 4.632
Authors: Nicholas Scott-Wittenborn; Gypsyamber D'Souza; Sakshi Tewari; Lisa Rooper; Tanya Troy; Virginia Drake; Elaine O Bigelow; Melina J Windon; William R Ryan; Patrick K Ha; Ana P Kiess; Brett Miles; William H Westra; Wojciech K Mydlarz; David W Eisele; Carole Fakhry Journal: Cancer Date: 2022-02-08 Impact factor: 6.921
Authors: Navkiran K Shokar; Amy Doan; Jessica Calderon-Mora; Rajkumar Lakshmanaswamy; Subramani Ramadevi; Gurjeet S Shokar; Jennifer Molokwu; Adam Alomari; Alok Dwivedi Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302